ArticleAntimicrobial agents and chemotherapy2010
Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
233 citing papers in PubMed, 1 synthesis or guideline pooled it, 408 citations in OpenAlex.
- Klebsiella pneumoniae: an increasing threat to public health.Annals of clinical microbiology and antimicrobials · 2020Pooled it
- Molecular typing and virulence analysis of multidrug resistant Klebsiella pneumoniae clinical isolates recovered from Egyptian hospitals.Scientific reports · 2016Trial
- Bacterial strategies for surviving antibiotics during urinary tract infection: could uropathogenic Escherichia coli be persisters?Nature reviews. Urology · 2026Review
- Rapid profiling of polymyxin B susceptibility in Gram-negative bacteria with a novel polymyxin-derived fluorescent probe.Journal of advanced research · 2026Article
- A newly identified homologous SxtPR efflux system contributes to sulfamethoxazole/trimethoprim susceptibility and pathogenesis inAntimicrobial agents and chemotherapy · 2026Article
- Molecular Epidemiology ofMicroorganisms · 2026Article
- Hi-C Metagenome Deconvolution of Double-Crested Cormorant (Microorganisms · 2026Article
- Molecular mechanism of transition-state inhibitors of bacterial antibiotic efflux pumps.npj antimicrobials and resistance · 2026Article
- How resistance-nodulation-division (RND) efflux pumps contribute to virulence.PLoS pathogens · 2026Review
- A Novel Ocellatin-P1 Isoform fromInternational journal of molecular sciences · 2026Article
- From colonization to invasion: genomic and phenotypic comparison of faecal and bloodstream isolates from the same patients.Journal of medical microbiology · 2026Article
- Genetic variants of AcrAB and OqxAB and the impact of efflux pump inhibition on ciprofloxacin and amikacin resistance in clinical isolates of Klebsiella pneumoniae from Lima, Peru.BMC microbiology · 2026Article
- Evaluation of a machine learning system for genomic antimicrobial susceptibility determination on a clinically representative test set.Microbiology spectrum · 2026Article
- RND-mediated efflux couples antimicrobial resistance and hypervirulence in contemporary Vibrio cholerae.PLoS pathogens · 2026Article
- Genomic characterization of multidrug-resistant Klebsiella pneumoniae from an outbreak in Northeastern Brazil: mechanisms of virulence and resistance.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Pharmacokinetic/pharmacodynamic relationships and development of resistance of enrofloxacin and cefquinome in combination therapy against Klebsiella pneumoniae in chicks.BMC veterinary research · 2026Article
- From Host-Derived Pressures to the Environmental Anti-Antimicrobial Peptides Resistome: Mechanisms, Reservoirs and Implications for Therapeutic Peptide Design.Marine drugs · 2026Review
- Characterization of multidrug-resistant ST978-KL103Microbiology spectrum · 2026Article
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Lipopeptide Engineering: From Natural Origins to Rational Design Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
173 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory infections caused by Klebsiella pneumoniae are characterized by high rates of mortality and morbidity. Management of these infections is often difficult, due to the high frequency of strains that are resistant to multiple antimicrobial agents. Multidrug efflux pumps play a major role as a mechanism of antimicrobial resistance in Gram-negative pathogens. In the present study, we investigated the role of the K. pneumoniae AcrRAB operon in antimicrobial resistance and virulence by using isogenic knockouts deficient in the AcrB component and the AcrR repressor, both derived from the virulent strain 52145R. We demonstrated that the AcrB knockout was more susceptible, not only to quinolones, but also to other antimicrobial agents, including beta-lactams, than the wild-type strain and the AcrR knockout. We further showed that the AcrB knockout was more susceptible to antimicrobial agents present in human bronchoalveolar lavage fluid and to human antimicrobial peptides than the wild-type strain and the AcrR knockout. Finally, the AcrB knockout exhibited a reduced capacity to cause pneumonia in a murine model, in contrast to the wild-type strain. The results of this study suggest that, in addition to contributing to the multidrug resistance phenotype, the AcrAB efflux pump may represent a novel virulence factor required for K. pneumoniae to resist innate immune defense mechanisms of the lung, thus facilitating the onset of pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.